To reach the next value inflection
LicenseRx asset brief
Prevention and Treatment of Herpes Virus Infection by Inhibition of the JMJD2 Family of Histone Demethylases
Probability of Success
12% · grade D · Medium data confidence
Model PoS 12% (grade D, medium data confidence). Strongest signals: Indication pull, Licensing readiness. Biggest drag: IP position.
Data maturity (22%)
40
Early / Discovery; clinical reference.
IP position (16%)
30
Protection lapsed or abandoned -- verify freedom to operate.
Modality feasibility (14%)
55
Cell/gene therapy -- high upside, heavy manufacturing and regulatory load.
Indication pull (14%)
70
Infectious Disease -- active buyer appetite.
Competitive whitespace (12%)
74
Multi-modal differentiation.
Translational evidence (12%)
54
Public evidence mentions: clinical.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →